The latest recommendation from ICICI Securities reflects confidence in Sun Pharma’s specialty growth strategy, underpinned by its acquisition of Checkpoint Therapeutics for a total potential outlay of USD 355 million. This acquisition secures access to Unloxcyt (cosibelimab)—an FDA-approved anti-PD-L1 monoclonal antibody for treating advanced cutaneous squamous cell carcinoma (cSCC), the second most common form of skin cancer. With annual deaths from advanced cSCC touching 15,000 in the U.S. alone, this product targets a high-unmet-need market and aligns seamlessly with Sun's existing oncology assets like Odomzo and Nidlegy.
Unloxcyt: A Differentiated and Approved Oncology Asset
The cornerstone of this acquisition is Unloxcyt, a drug approved in the U.S. for both locally advanced and metastatic cSCC, with no contraindications and a manageable once-every-three-weeks dosing regimen. What makes Unloxcyt notable? It's the only anti-PD-L1 monoclonal antibody approved for this indication. Competes with Regeneron’s Libtayo (~USD 1.22 billion in 2024 sales) and Merck’s Keytruda (USD 28.5 billion). Sun Pharma could potentially leverage its U.S. salesforce and infrastructure to maximize its commercial success. The company expects European filings to follow shortly, expanding the product’s global addressable market.
Checkpoint’s Pipeline Enhances Long-Term Value
Beyond Unloxcyt, Checkpoint brings a portfolio of promising early-stage oncology molecules: Olafertinib: A third-generation EGFR inhibitor, potentially effective for non-small-cell lung cancer. CK-103: A BET inhibitor for solid tumors and myelofibrosis. CK-302: An anti-GITR therapy for solid tumors. CK-303: Targets CAIX, relevant for renal carcinoma. While Checkpoint is currently pre-revenue, with FY24 revenue at just USD 0.04 million and a net loss of USD 27.3 million, ICICI notes that the risk-reward profile is favorable due to Sun Pharma’s cash reserves and commercial expertise.
Financial Strength to Support Strategic Bets
At the end of Q3FY25, Sun Pharma had a net cash balance of USD 3 billion, making it well-positioned to fund the acquisition and absorb near-term R&D cost escalations without compromising profitability.
Key financial metrics from ICICI Securities:
| Metric | FY25E | FY26E | FY27E |
|---|---|---|---|
| Net Revenue (Rs. Cr) | 5,25,617 | 5,80,820 | 6,20,560 |
| EBITDA (Rs. Cr) | 1,49,552 | 1,69,521 | 1,78,749 |
| PAT (Rs. Cr) | 1,18,675 | 1,37,782 | 1,46,552 |
| EPS (Rs.) | 49.5 | 57.4 | 61.1 |
| P/E (x) | 34.1 | 28.1 | 26.4 |
| ROE (%) | 17.6 | 18.1 | 17.2 |
Market Valuation and Rationale for Upgrade
Sun Pharma’s stock has seen a 10% correction over the last two months, which ICICI views as a buying opportunity. The stock currently trades at: 28x FY26E EPS 26.4x FY27E EPS EV/EBITDA of 19.3x FY27E ICICI’s target price of Rs. 1,895 is based on 31x FY27E EPS, up from the earlier Rs. 1,840 target. The brokerage expects key catalysts like the commercialization of Unloxcyt and Leqselvi to unlock value over FY27–28.
Strategic Synergies and Product Positioning
The acquisition complements Sun’s strategy to build a high-margin, specialty-focused pharmaceutical portfolio, particularly in dermatology and oncology. Unloxcyt will fit seamlessly with Odomzo and Nidlegy, potentially benefiting from the same marketing and sales channels. Additionally, Sun is developing GLP-1 agonist utreglutide for diabetes and obesity—another major pipeline asset expected over the next 4–5 years.
Risks and Forward-Looking View
While the outlook is bullish, ICICI outlines key downside risks: Regulatory delays in Unloxcyt’s EU approval or Checkpoint shareholder pushback. Escalating R&D expenses post-acquisition. U.S. pricing pressures and generic competition in base portfolio. However, given Sun Pharma’s cash reserves, global reach, and pipeline depth, ICICI expects the company to navigate these risks effectively.
Conclusion: Buy the Dip, Bet on Specialty Leadership
With robust cash flows, a healthy balance sheet, and a clear commitment to innovative therapies, Sun Pharma is well-positioned to become a global leader in specialty pharmaceuticals. The Checkpoint acquisition, anchored by Unloxcyt’s FDA approval and a deep oncology pipeline, enhances its competitive edge. Investors looking for long-term growth with downside protection may find Sun Pharma an attractive proposition at current levels.
Comments